Immune to Cancer: The CRI Blog
-
FDA Approves New Cancer Immunotherapy
Merck's new immunotherapy, Keytruda (pembrolizumab), was approved today by the FDA, making it the first PD-1 inhibitor…
-
Two Immunotherapies Clear Important Regulatory Hurdles
The anti-PD-1 drug nivolumab receives the go-ahead for use in Japan, while in the U.S., CAR-T cells…